A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Camostat mesilate (Primary)
- Indications Pancreatitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Stason Pharmaceuticals
- 07 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
- 07 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 30 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.